Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 28 people, all of whom received the study drug enzastaurin (27 received at least one dose, and 27 completed the study). The trial was measuring how many participants went at least six months without their cancer getting worse (called "progression-free survival at six months"), as well as tracking how long participants lived without their disease worsening, how long they survived overall, and how many experienced unwanted side effects. The reported data shows that 10% of participants (roughly 2–3 people out of 27) reached the six-month mark without their disease progressing or dying. The reported median time before the disease progressed was 1.9 months — meaning that, on average, half the participants reached that point before 1.9 months and half after. The reported median overall survival (time from diagnosis to death from any cause) was 15.1 months. Regarding side effects, the data shows that all 27 participants who received the drug experienced at least one adverse event (an unwanted or unexpected health event), and 12 of those 27 experienced a serious adverse event. The reported data also shows that 17 participants were classed as resistant to a prior platinum-based treatment, 9 were sensitive to it, and 1 was not categorised; separately, 16 participants had a fully active performance status and 11 had a mildly restricted one. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have ovarian cancer or primary peritoneal cancer that has come back or has not gone away after treatment.
- Your cancer can be measured on scans or tests, and there is at least one specific area of cancer that doctors can track to see if the treatment is working.
- You are not eligible for a higher-priority study through the Gynecologic Oncology Group (GOG) at the time of joining.
- If you have had one previous cancer treatment, your general health and ability to carry out daily activities meets a certain minimum standard; if you have had two previous treatments, your health and activity level must meet a slightly higher standard (confirm with trial site).
- You have previously had at least one chemotherapy treatment containing a platinum-based drug (such as carboplatin or cisplatin) for your primary diagnosis.
- Any hormone therapy aimed at your cancer has been stopped for at least one week before joining; regular hormone replacement therapy (e.g., for menopause) is allowed to continue.
- Any other cancer treatments (including immunotherapy) have been stopped for at least four weeks before joining.
- If you are able to become pregnant, you have had a negative pregnancy test before starting and are using an effective form of contraception during the study and for 3 months after finishing treatment.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have previously been treated with the drug enzastaurin.
- You have had radiation therapy covering more than 25% of the areas in your body where bone marrow is produced.
- You have had another serious (invasive) cancer in the last 5 years, apart from certain common skin cancers, or your previous cancer treatment would make this trial unsafe for you.
- You have received an experimental drug (one not yet officially approved) within the last 30 days before joining.
- You are unable to stop taking certain anti-seizure medications, specifically carbamazepine, phenobarbital, or phenytoin (confirm with trial site).
- You are currently receiving any other systemic cancer treatment, except for a bone-strengthening medication (bisphosphonate) if your cancer has spread to your bones.
- You have previously received a non-chemotherapy cancer treatment, such as bevacizumab (a targeted therapy drug).
- You have a serious ongoing health condition — such as an active infection or a heart problem showing on an ECG — that the study doctor believes could put you at risk or prevent you from completing the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Progression-free Survival for at Least 6 Months (PFS-6); Number of Participants With Adverse Events and Severe Adverse Events
Other options
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.